Fundamental functionality: Recent developments in understanding the structure-activity relationships of lantibiotic peptides

Journal of Antibiotics

Volumn 64, Issue 1, 2011, Pages 27-34

  Ross, Avena C ^a   Vederas, John C ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

antimicrobial peptide; lantibiotics; mutagenesis; structural variant; structure activity

Indexed keywords

HALODURACIN; LACTICIN 3147 A1; LACTICIN 3147 A2; LACTICIN 481; LANTIBIOTIC; MERSACIDIN; NISIN A; NISIN Z; NUKACIN ISK 1; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; CLOSTRIDIUM BOTULINUM; FOOD PRESERVATION; FOOD SAFETY; FOOD SPOILAGE; LACTOCOCCUS LACTIS; LISTERIA MONOCYTOGENES; MEMBRANE BINDING; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STRUCTURE ACTIVITY RELATION;

ANIMALS; BACTERIOCINS; HUMANS; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79251639867     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2010.136     Document Type: Review

References (47)

1. Li, J. W.- H. & Vederas, J. C. Drug discovery and natural products: End of an era or an endless frontier? Science 325, 161-165 (2009).
2. Fernandes, P. B. et al. In vitro and in vivo evaluation of A-56268 (TE-031): A new macrolide. Antimicrob. Agents Chemother. 30, 865-873 (1986).
3. Draper, L. A., Ross, R. P., Hill, C. & Cotter, P. D. Lantibiotic immunity. Curr. Protein Peptide Sci. 9, 39-49 (2008).
4. Bierbaum, G. & Sahl, H.- G. Lantibiotics: Mode of action, biosynthesis and bioengineering. Curr. Pharm. Biotechnol. 10, 2-18 (2009).
5. Willey, J. M. & van der Donk, W. A. Lantibiotics: Peptides of diverse structure and function. Annu. Rev. Microbiol. 61, 477-501 (2007).
6. Chatterjee, C., Paul, M., Xie, L. & van der Donk, W. A. Biosynthesis and mode of action of lantibiotics. Chem. Rev. 105, 633-683 (2005).
7. Cotter, P. D., Hill, C. & Ross, R. P. Bacterial lantibiotics: Strategies to improve therapeutic potential. Curr. Protein Peptide Sci. 6, 61-75 (2005).
8. Oman, T. J. & van der Donk, W. A. Insights into the mode of action of the twocomponent lantibiotic haloduracin. ACS Chem. Biol. 4, 865-874 (2009).
9. Wiedemann, I. et al. The mode of action of the lantibiotic lacticin 3147- a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol. Microbiol. 61, 285-296 (2006).
10. Wilson-Stanford, S. et al. Oxidation of lanthionines renders the lantibiotic nisin inactive. Appl. Environ. Microbiol. 75, 1381-1387 (2009).
11. Asaduzzaman, S. M. & Sonomoto, K. Lantibiotics: Diverse activities and unique modes of action. J. Biosci. Bioeng. 107, 475-487 (2009).
12. Lubelski, J., Rink, R., Khusainov, R., Moll, G. N. & Kuipers, O. P. Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin. Cell Mol. Life Sci. 65, 455-476 (2008).
13. Rink, R. et al. Dissection and modulation of the four distinct activities of nisin by mutagenesis of rings A and B and by C-terminal truncation. Appl. Environ. Microbiol. 73, 5809-5816 (2007).
14. Field, D., O'Connor, P. M., Cotter, P. D., Hill, C. & Ross, R. P. The generation of nisin variants with enhanced activity against specific gram-positive pathogens. Mol. Microbiol. 69, 218-230 (2008).
15. Rince, A. et al. Cloning, expression and nucleotide sequence of genes involved in production of lactococcin DR, a bacteriocin from Lactococcus lactis subsp. lactis. Appl. Environ. Microbiol. 60, 1652-1657 (1994).
16. Piard, J.- C., Muriana, P. M., Desmazeaud, M. J. & Klaenhammer, T. R. Purification and partial characterization of lacticin 481, a lanthionine-containing bacteriocin produced by Lactococcus lactis subsp. lactis CNRZ 481. Appl. Environ. Microbiol. 58, 279-284 (1992).
17. Xie, L. et al. Lacticin 481: In vitro reconstitution of lantibiotic synthetase activity. Science 303, 679-681 (2004).
18. Uguen, P. et al. Maturation by LctT is required for biosynthesis of full-length lantibiotic lacticin 481. Appl. Environ. Microbiol. 71, 562-565 (2005).
19. Patton, G. C. & van der Donk, W. A. New developments in lantibiotic biosynthesis and mode of action. Curr. Opin. Microbiol. 8, 543-551 (2005).
20. Cooper, L. E., McClerren, A. L., Chary, A. & van der Donk, W. A. Structure-activity relationship studies of the two-component lantibiotic haloduracin. Chem. Biol. 15, 1035-1045 (2008).
21. Szekat, C., Jack, R. W., Skutlarek, D., Färber, H. & Bierbaum, G. Construction of an expression system for site-directed mutagenesis of the lantibiotic mersacidin. Appl. Environ. Microbiol. 69, 3777-3783 (2003).
22. Appleyard, A. N. et al. Dissecting structural and functional diversity of the lantibiotic mersacidin. Chem. Biol. 16, 490-498 (2009).
23. Chatterjee, C., Patton, G. C., Cooper, L., Paul, M. & van der Donk, W. A. Engineering dehydro amino acids and thioethers into peptides using lacticin 481 synthetase. Chem. Biol. 13, 1109-1117 (2006).
24. Dufour, A., Hindré , T., Haras, D. & Le Pennec, J.- P. The biology of lantibiotics from the lacticin 481 group is coming of age. FEMS Microbiol. Rev. 31, 134-167 (2007).
25. Hindré, T. et al. Bacteriocin detection from whole bacteria by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Appl. Environ. Microbiol. 69, 1051-1058 (2003).
26. Levengood, M. R., Knerr, P. J., Oman, T. J. & van der Donk, W. A. In vitro mutasynthesis of lantibiotic analogues containing nonproteinogenic amino acids. J. Am. Chem. Soc. 131, 12024-12025 (2009).
27. Kimura, H., Nagano, R., Matsusaki, H., Sonomoto, K. & Ishizaki, A. A bacteriocin of strain Pediococcus sp. ISK-1 isolated from nukadoko, bed of fermented rice bran. Biosci., Biotechnol., Biochem. 61, 1049-1051 (1997). (Pubitemid 27369498)
28. Sashihara, T. et al. A novel lantibiotic, ISK-1, of Staphylococcus warneri ISK-1: Cloning of the structural gene and identification of the structure. Biosci., Biotechnol., Biochem. 64, 2420-2428 (2000).
29. Islam, M. R. et al. Evaluation of essential and variable residues of nukacin ISK-1 by NNK scanning. Mol. Microbiol. 72, 1438-1447 (2009).
30. Asaduzzaman, S. M., Nagao, J.-i., Aso, Y., Nakayama, J. & Sonomoto, K. Lysineoriented charges trigger the membrane binding and activity of nukacin ISK-1. Appl. Environ. Microbiol. 72, 6012-6017 (2006).
31. Chatterjee, S. et al. Mersacidin, a new antibiotic from bacillus fermentation, isolation, purification and chemical characterisation. J. Antibiot. 45, 832-838 (1992).
32. Chatterjee, S. et al. Mersacidin, a new antibiotic from bacillus in vitro and in vivo antibacterial activity. J. Antibiot. 45, 839-845 (1992).
33. Kruszewska, D. et al. Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitic model. J. Antimicrob. Chemother. 54, 648-653 (2004).
34. Brötz, H., Bierbaum, G., Leopold, K., Reynolds, P. E. & Sahl, H.- G. The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob. Agents Chemother. 42, 154-160 (1998).
35. Ryan, M. P., Rea, M. C., Hill, C. & Ross, R. P. An application in cheddar cheese manufacture for a strain of Lactococcus lactis producing a novel broad-spectrum bacteriocin, lacticin 3147. Appl. Environ. Microbiol. 62, 612-619 (1996).
36. Martin, N. I. et al. Structural characterization of lacticin 3147, a two-peptide lantibiotic with synergistic activity. Biochemistry 43, 3049-3056 (2004).
37. Ryan, M. P., Meaney, W. J., Ross, R. P. & Hill, C. Evaluation of lacticin 3147 and a teat seal containing this bacteriocin for inhibition of mastitis pathogens. Appl. Environ. Microbiol. 64, 2287-2290 (1998).
38. Ross, R. P. et al. Developing applications for lactococcal bacteriocins. Antonie Van Leeuwenhoek 76, 337-346 (1999).
39. Cotter, P. D. et al. Posttranslational conversion of L-serines to D-alanines is vital for optimal production and activity of the lantibiotic lacticin 3147. Proc. Natl Acad. Sci. USA 102, 18584-18589 (2005).
40. Cotter, P. D. et al. Complete alanine scanning of the two-component lantibiotic lacticin 3147: Generating a blueprint for rational drug design. Mol. Microbiol. 62, 735-747 (2006).
41. Field, D., Collins, B., Cotter, P. D., Hill, C. & Ross, R. P. A system for the random mutagenesis of the two-peptide lantibiotic lacticin 3147: Analysis of mutants producing reduced antibacterial activities. J. Mol. Microbiol. Biotechnol. 13, 226-234 (2007).
42. O'Connor, E. B. et al. Relatedness between the two-component lantibiotics lacticin 3147 and staphylococcin C55 based on structure, genetics and biological activity. BMC Microbiol. 7, 24-38 (2007).
43. Pattabiraman, V. R., McKinnie, S. M. K. & Vederas, J. C. Solid-supported synthesis and biological evaluation of the lantibiotic peptide Bis (desmethyl) lacticin 3147 A2. Angew. Chem. Int. Ed. 47, 9472-9475 (2008).
44. Liu, H., Pattabiraman, V. R. & Vederas, J. C. Synthesis and biological activity of oxa-lacticin A2, a lantibiotic analogue with sulfur replaced by oxygen. Org. Lett. 11, 5574-5577 (2009).
45. Pattabiraman, V. R., Stymiest, J. L., Derksen, D. J., Martin, N. I. & Vederas, J. C. Multiple on-resin olefin metathesis to form ring-expanded analogues of the lantibiotic peptide, lacticin 3147 A2. Org. Lett. 9, 699-702 (2007).
46. McClerren, A. L. et al. Discovery and in vitro biosynthesis of haloduracin, a twocomponent lantibiotic. Proc. Natl Acad. Sci. USA 103, 17243-17248 (2006).
47. Yoganathan, S. & Vederas, J. C. Fracturing rings to understand lantibiotics. Chem. Biol. 15, 999-1001 (2008).